<i><scp>CYP</scp>2C19</i> Polymorphisms and Therapeutic Drug Monitoring of Voriconazole: Are We Ready for Clinical Implementation of Pharmacogenomics?

Abstract excerpt

Since its approval by the U.S. Food and Drug Administration in 2002, voriconazole has become a key component in the successful treatment of many invasive fungal infections including the most common, aspergillosis and candidiasis. Despite voriconazole's widespread use, optimizing its treatment in an individual can be challenging due to significant interpatient variability in plasma concentrations of the drug....

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Antifungal resistance and susceptibility
• Share to Microbial Natural Products and Biosynthesis
• Share to Pharmacogenetics and Drug Metabolism